

ASX ANNOUNCEMENT

XANAMEM™ RESEARCH PRESENTED AT CTAD

Sydney, 6 December 2016: Actinogen Medical Limited (ASX:ACW) is pleased to announce the presentation of the latest Xanamem™ research data at CTAD (Clinical Trials in Alzheimer's Disease) in San Diego. The paper: *Xanamem™: an 11β-HSD1 Inhibitor in current development for the management of Alzheimer's disease (AD)*, will be presented by Prof Craig Ritchie on Friday the 9th December.

CTAD is one of the most prestigious international Alzheimer's congresses, where the latest ground-breaking research into Alzheimer's disease is showcased. CTAD focuses on promising new Alzheimer's drugs under development. This presentation follows on from the very successful presentations of Xanamem™ at AAIC (Alzheimer's Association International Congress) in Toronto, ICE (the International Congress of Endocrinology) in Beijing and Mastering Medicinal Chemistry in Lisbon, over the past few months.

These presentations, along with the imminent publication of the latest Xanamem™ research in a major medical journal, substantially add to the knowledge database on, and awareness of, Xanamem™. Actinogen Medical looks forward to further add to this knowledge base with the start of patient recruitment into XanADu, the Phase II trial of Xanamem™ in mild Alzheimer's disease, early in 2017.

Xanamem™ is specifically designed to block excess production of cortisol, the stress hormone, in the areas of the brain most affected in the early stages of Alzheimer's disease. Raised cortisol has been clearly associated with the development and progression of Alzheimer's disease. Actinogen Medical is running XanADu, a global clinical trial of Xanamem™ in patients with mild Alzheimer's disease, to confirm earlier research results that demonstrated that Xanamem™ could successfully treat Alzheimer's disease in an animal model of the disease.

Alzheimer's disease is one of the biggest public health challenges for modern society and our health systems. It's the biggest killer in the UK and second only to heart disease in Australia. Current medicines to treat Alzheimer's provide only marginal benefit and new therapies are desperately needed to help manage this devastating disease. Actinogen Medical hopes to demonstrate that Xanamem™ is an effective new treatment for Alzheimer's disease within the next two years.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease.